TRANSINE
LIVE

Serial Number

79316838

Owner

Harness Therapeutics Limited

Attorney

Rebecca Liebowitz

Filing Date

Feb 11, 2021

Add to watchlist:

No watchlists yet
View on USPTO

TRANSINE Trademark

Serial Number: 79316838 • Registration: 6816931

TRANSINE is a trademark filed by Harness Therapeutics Limited on February 11, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Harness Therapeutics Limited (4 trademarks)

Minerva Building (B250),

Entity Type: 98

Transine Therapeutics Limited (2 trademarks)

30 Broad Street,

Entity Type: 99

Trademark Details

Filing Date

February 11, 2021

Registration Date

August 16, 2022

Published for Opposition

May 31, 2022

Goods & Services

Pharmaceutical preparations for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical and veterinary preparations for therapeutic purposes for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; biological, chemical and biochemical reagents, namely, DNA and RNA sequences and gene editing enzymes, all for medical use; DNA and RNA products for medical use, namely, nucleic acid sequences for medical purposes; therapeutic DNA and RNA, namely, nucleic acid sequences for medical purposes

Chemical preparations for scientific purposes, other than for medical or veterinary use; chemicals for research use, namely, nucleic acid sequences for laboratory or research use; enzymes for research use; DNA and RNA for research use, namely, nucleic acid sequences for laboratory use, nucleic acid sequences for other than medical and veterinary purposes; chemicals for use in the preparation and creation of DNA and RNA, reagents for scientific purposes, other than for medical or veterinary use; enzymes for use in the preparation and creation of DNA and RNA, namely, enzymes for scientific and research purposes; molecular biology research tools in the nature of biological, chemical and biochemical reagents for research use

Scientific and technological services and research and design relating thereto, namely scientific research services in the field of genomics; medical research services including the manipulation of biological reagents to be used for medical or therapeutic purposes; chemical and biological analysis and research services; scientific research into DNA and RNA; research and development into the creation of DNA and RNA; research, development, testing and analysis for scientific research purposes in the field of genomics, DNA and RNA sequencing, gene synthesis, gene identification, gene cloning, gene expression, gene mapping; scientific research in the field of molecular biology, next generation sequencing, high-throughput sequencing and bioinformatics; gene editing services for scientific research purposes; DNA and RNA modelling services, namely genetic mapping for scientific purposes; gene engineering services; research and development services in the creation of genome libraries or collections of biologicals including chemicals and compounds; creating and providing databases or collections of information on normal and mutated genes for scientific research purposes; scientific services relating to the discovery, preclinical and clinical development of therapeutic products, namely therapeutic DNA and RNA; consultancy and advisory services relating to the aforesaid services; research and development of synthetic DNA, RNA, genes and oligonucleotides for others

Filing History

CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 21, 2025 ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 2, 2024 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 21, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 26, 2022 FICS
FINAL DISPOSITION PROCESSED
Nov 26, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 16, 2022 FICR
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Oct 26, 2022 LIMN
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 16, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 16, 2022 R.PR
LIMITATION OF GOODS RECEIVED FROM IB
Jun 20, 2022 LIMG
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 31, 2022 NPUB
PUBLISHED FOR OPPOSITION
May 31, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 11, 2022 NONP
ASSIGNED TO LIE
Apr 25, 2022 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 22, 2022 CNSA
ASSIGNED TO EXAMINER
Mar 25, 2022 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 16, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 15, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 15, 2022 TROA
REFUSAL PROCESSED BY IB
Oct 4, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 16, 2021 RFCS
REFUSAL PROCESSED BY MPU
Sep 16, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 2, 2021 RFCR
NON-FINAL ACTION WRITTEN
Sep 1, 2021 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Aug 27, 2021 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 13, 2021 RFCR
NON-FINAL ACTION WRITTEN
Aug 12, 2021 CNRT
APPLICATION FILING RECEIPT MAILED
Aug 10, 2021 MAFR
ASSIGNED TO EXAMINER
Aug 9, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 5, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 29, 2021 REPR